Literature DB >> 16832088

Medication-overuse headache in patients with cluster headache.

K Paemeleire1, A Bahra, S Evers, M S Matharu, P J Goadsby.   

Abstract

OBJECTIVE: Medication-overuse headache (MOH) in cluster headache (CH) patients is incompletely described, perhaps because of the relatively low prevalence of CH.
METHODS: The authors describe a retrospective series of 17 patients (13 men, 4 women) with CH who developed MOH in association with overuse of a wide range of monotherapies or varying combinations of simple analgesics (n = 9), caffeine (n = 1), opioids (n = 10), ergotamine (n = 3), and triptans (n = 14). The series includes both episodic (n = 7) and chronic (n = 10) CH patients.
RESULTS: A specific triptan-overuse headache diagnosis was made in 3 patients, an opioid-overuse headache diagnosis was made in 1 patient, and an ergotamine-overuse headache diagnosis was made in 1 patient. In approximately half of the patients (n = 8), the MOH phenotype was a bilateral, dull, and featureless daily headache. In the other 9 patients, the MOH was characterized by at least one associated feature, most commonly nausea (n = 6), exacerbation with head movement (n = 5), or throbbing character of the pain (n = 5). The common denominator in 15 patients was a personal or family history, or both, of migraine. The 2 other patients gave a family history of unspecified headaches. Medication withdrawal was attempted and successful in 13 patients.
CONCLUSIONS: Medication-overuse headache is a previously underrecognized and treatable problem associated with cluster headache (CH). CH patients should be carefully monitored, especially those with a personal or family history of migraine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832088     DOI: 10.1212/01.wnl.0000223332.35936.6e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Gregory Dussor; Josephine Lai; Ian D Meng; Juliana Chichorro; John S Andrews; Suman Rakhit; Shawn Maddaford; David Dodick; Frank Porreca
Journal:  Brain       Date:  2010-07-13       Impact factor: 13.501

2.  Headache disorders: differentiating and managing the common subtypes.

Authors:  Fayyaz Ahmed
Journal:  Br J Pain       Date:  2012-08

Review 3.  Oral triptans in the preventive management of cluster headache.

Authors:  Lutz Pageler; Volker Limmroth
Journal:  Curr Pain Headache Rep       Date:  2012-04

Review 4.  Medication-overuse headache: epidemiology, diagnosis and treatment.

Authors:  Espen Saxhaug Kristoffersen; Christofer Lundqvist
Journal:  Ther Adv Drug Saf       Date:  2014-04

Review 5.  Cluster Headache: A Review and Update in Treatment.

Authors:  Himanshu Suri; Jessica Ailani
Journal:  Curr Neurol Neurosci Rep       Date:  2021-05-05       Impact factor: 5.081

Review 6.  Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Authors:  Ian D Meng; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2011-03-28       Impact factor: 6.292

Review 7.  Medication Overuse Headache: The Reason of Headache That Common and Preventable.

Authors:  Elif Kocasoy Orhan; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 8.  Medication-overuse headache: risk factors, pathophysiology and management.

Authors:  Hans-Christoph Diener; Dagny Holle; Kasja Solbach; Charly Gaul
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

Review 9.  [Current diagnosis and treatment of migraine].

Authors:  H-C Diener; Z Katsarava; V Limmroth
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

Review 10.  [Therapy of primary chronic headache: chronic migraine, chronic tension type headache and other forms of daily chronic headache].

Authors:  A Straube; A May; P Kropp; Z Katsarava; G Haag; C Lampl; P S Sándor; H-C Diener; S Evers
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.